Budgeting for the new therapy remains a huge challenge, but with emerging evidence and pricing dynamics, plan sponsors should revisit older cost-benefit analyses
For patients with severe obesity and metabolic disease, they save lives
That enforcement activity is ongoing and accelerating
GLP-1 exerts its biological effects by binding to a specific receptor (GLP-1R), which is expressed in different types of peripheral tissues and in the central nervous system [12]
With orforglipron, its a newer, non-peptide version of a GLP-1, so we dont yet have the same depth of safety data as the injectables. A spokesperson for the Department of Health and Human Services, which oversees the FDA, didnt immediately respond to a request for comment